Efficacy of trimetazidine in the treatment of ischemic cardiomyopathy
曲美他嗪用于缺血性心肌病临床治疗的有效性研究

摘要

目的 探究曲美他嗪在缺血性心肌病患者临床治疗的效果和影响。方法 以2020年8月至2021年8月该院收治的112例缺血性心肌病患者为研究对象，按照系统随机分组原则分为常规治疗组（对照组）和联合治疗组（研究组）两组，均分为56例/组。其中对照组按照常规治疗药剂进行常规性治疗，研究组在常规治疗方法的基础上，采用加入曲美他嗪药物的联合治疗方案。观察两组患者的整体治疗效果以及相关机体指标、数据变化。结果 通过数据对比以及康复情况诊查，研究组患者的机体指标恢复情况以及治疗有效率明显优于对照组患者（研究组患者的治疗有效率为96.4%，对照组患者的治疗有效率82.1%），检验结果显示差异有统计学意义（P<0.05）。研究组心功能改善情况效果显著，且身体机能指标提升优于对照组（P<0.05）。结论 临床治疗过程中采用常规药物+曲美他嗪药物联合治疗对缺血性心肌病患者的病情改善有明显效果，有较高的应用和推广价值。

Abstract

Objective: To explore the clinical effect and influence of trimetazidine in patients with ischemic cardiomyopathy.
Methods: A total of 112 patients with ischemic cardiomyopathy admitted to our hospital from August 2020 to August 2021 were selected as the study subjects. They were divided into two groups according to the principle of systematic randomization: conventional treatment group (control group) and combined treatment group (research group), each of which was divided into 56 cases/group. The control group received conventional treatment according to conventional treatment agents, and the research group received combined treatment with trimetazidine on the basis of conventional treatment methods. The overall therapeutic effect and the changes of relevant body indicators and data were observed in the two groups.
Results: Through data comparison and rehabilitation diagnosis, the body index recovery and treatment efficiency of patients in the study group were significantly better than those in the control group (the treatment efficiency of patients in the study group was 96.4%, the treatment efficiency of patients in the control group was 82.1%), the test results showed that the difference was statistically significant (P<0.05). The improvement of cardiac function in the study group was significant, and the improvement of physical function index was better than that in the control group (P<0.05).
Conclusion  : The combination of conventional drugs and trimetazidine in clinical treatment has obvious effect on the improvement of the condition of patients with ischemic cardiomyopathy, and has high application and promotion value.